USA Patient Network

Articles, Letters, and Testimony

Patient Advocates’ Comments to the FDA on Metals in Implants

Immunology Devices Panel of the Medical Devices Advisory Committee;

Notice of Meeting; Establishment of a Public Docket; Request for Comments

Docket No. FDA-2019-N-3767

Patient Safety Action Network’s Medical Device Roundtable

Advocating Safety in Healthcare E-Sisters (ASHES)

Washington Advocates for Patient Safety

Breast Implant Victim Advocacy

Breast Implant Safety Allianc...

February 26, 2018

We believe that there is no need for the proposed Right To Try Legislation (RTT). A pathway to such access already exists through the FDA’s Expanded Access program.

June 12, 2017

In accomplishing the goal of developing a nuanced understanding of the patient experience by disease, it is critical that any future Office of Patient Affairs at the FDA (OPA-FDA) be conscious of the broad range of diseases and patient experiences, and deliberate in drawing out and responding to the full spectrum of the patient experience and voice in terms of what is clinically meaningful.

February 24, 2017

The USA Patient Network outlines the risks of supporting the Right to Try Act and asks senators to withdraw their support.

February 22, 2017

The USA Patient Network thanks senators for not co-sponsoring the Trickett Wendler Right to Try Act because it would put patients in harm’s way.

January 6, 2017

Our comments are focused on the issues of inclusion and barriers to participation, but also on the broader issue of making sure that patients’ perspectives are truly representative of all patients, and that issues of safety and effectiveness of medical devices are at the forefront.

December 5, 2016

The USA Patient Network respectfully and strongly urges senators to vote against the 21st Century Cures Act this week, and instead insist that the bill be improved and more carefully vetted in 2017.

November 10, 2016

The USA Patient Network respectfully urges senators to not advance the Senate’s Innovation for Healthier Americans bills or the House’s 21st Century Cures Act during the lame-duck session of Congress, but instead wait for when they have more time to carefully weigh each aspect of the bills in 2017.

Please reload

Please reload

“It often takes months or even years for the F.D.A. to detect patterns of failure,” said Jack Mitchell, director of health policy for the National Center for Health Research in Washington. “Post-market surveillance of medical devices continues to be dangerously slow an...

Please reload

© 2016 by The National Center for Health Research. 

  • Facebook Clean
  • Twitter Clean